Advertisement

 

 

Midwife or doctor local opinion leader to implement a national guideline in babies on postnatal wards (DesIGN): protocol of a cluster-randomised, blinded, controlled trial.

Midwife or doctor local opinion leader to implement a national guideline in babies on postnatal wards (DesIGN): protocol of a cluster-randomised, blinded, controlled trial.
Author Information (click to view)

Alsweiler JM, Crowther CA, Harding JE,


Alsweiler JM, Crowther CA, Harding JE, (click to view)

Alsweiler JM, Crowther CA, Harding JE,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

BMJ open 2017 11 227(11) e017516 doi 10.1136/bmjopen-2017-017516
Abstract
INTRODUCTION
Neonatal hypoglycaemia is a common condition that can cause developmental delay. Treatment of neonatal hypoglycaemia with oral dextrose gel has been shown to reverse hypoglycaemia and reduce admissions to neonatal intensive care for hypoglycaemia. An evidence-based clinical practice guideline was written to guide the use of dextrose gel to treat neonatal hypoglycaemia in New Zealand. However, it is unclear what clinical discipline might most effectively lead the implementation of the guideline recommendations.

OBJECTIVE
To determine if midwife or doctor local opinion leaders are more effective in implementing a clinical practice guideline for use of oral dextrose gel to treat hypoglycaemia in babies on postnatal wards.

METHODS AND ANALYSIS
A cluster-randomised, blinded, controlled trial. New Zealand maternity hospitals that care for babies born at risk of neonatal hypoglycaemia will be randomised to having either a local midwife or doctor lead the guideline implementation at that hospital. The primary outcome will be the change in the proportion of hypoglycaemic babies treated with dextrose gel from before implementation of the guideline to 3 months after implementation.

ETHICS AND DISSEMINATION
Approved by Health and Disability Ethics Committee: 15/NTA/31. Findings will be disseminated to peer-reviewed journals, guideline developers and the public.

TRIAL REGISTRATION NUMBER
ISRCTN61154098.

Submit a Comment

Your email address will not be published. Required fields are marked *

20 − 6 =

[ HIDE/SHOW ]